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Fatty acid binding protein
deletion suppresses inflammatory pain
through endocannabinoid/
N‑acylethanolamine‑dependent mechanisms
Martin Kaczocha1*†, Sherrye T. Glaser2†, Thomas Maher3, Brendan Clavin3, John Hamilton3, Joseph O’Rourke3,
Mario Rebecchi1, Michelino Puopolo1, Yuji Owada4 and Panayotis K. Thanos3

Abstract
Background: Fatty acid binding proteins (FABPs) serve as intracellular carriers that deliver endocannabinoids and
N-acylethanolamines to their catabolic enzymes. Inhibition of FABPs reduces endocannabinoid transport and catabolism in cells and FABP inhibitors produce antinociceptive and anti-inflammatory effects in mice. Potential analgesic
effects in mice lacking FABPs, however, have not been tested.
Findings: Mice lacking FABP5 and FABP7, which exhibit highest affinities for endocannabinoids, possessed elevated
levels of the endocannabinoid anandamide and the related N-acylethanolamines palmitoylethanolamide and oleoylethanolamide. There were no compensatory changes in the expression of other FABPs or in endocannabinoid-related
proteins in the brains of FABP5/7 knockout mice. These mice exhibited reduced nociception in the carrageenan, formalin, and acetic acid tests of inflammatory and visceral pain. The antinociceptive effects in FABP5/7 knockout mice
were reversed by pretreatment with cannabinoid receptor 1, peroxisome proliferator-activated receptor alpha, and
transient receptor potential vanilloid 1 receptor antagonists in a modality specific manner. Lastly, the knockout mice
did not possess motor impairments.
Conclusions: This study demonstrates that mice lacking FABPs possess elevated levels of N-acylethanolamines, consistent with the idea that FABPs regulate the endocannabinoid and N-acylethanolamine tone in vivo. The antinociceptive effects observed in the knockout mice support a role for FABPs in regulating nociception and suggest that these
proteins should serve as targets for the development of future analgesics.
Keywords: Fatty acid binding protein, FABP, Endocannabinoid, Anandamide, Pain
Findings
Background

Fatty acid binding proteins (FABPs) are intracellular
lipid chaperones that are expressed in cells of the central and peripheral nervous system [1–3]. In addition to
fatty acids, FABPs interact with other endogenous lipids
including the endocannabinoids, anandamide (AEA) and
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2-arachidonoylglycerol (2-AG), and related N-acylethanolamines (NAEs) [4–7]. Endocannabinoids activate cannabinoid receptor 1 (CB1) to produce antinociceptive
effects [8, 9]. Similarly, the NAEs palmitoylethanolamide
(PEA) and oleoylethanolamide (OEA) activate peroxisome proliferator-activated receptor alpha (PPARα)
centrally and peripherally to produce analgesic and antiinflammatory effects [10, 11].
We have previously shown that FABP5 and FABP7
bind to endocannabinoids/NAEs with high affinities
[5, 12]. FABPs mediate the intracellular trafficking of
endocannabinoids/NAEs to their catabolic enzyme(s)
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such as fatty acid amide hydrolase (FAAH) [4]. Consequently, inhibition of FABPs reduces endocannabinoid
uptake and inactivation [4]. Recently, we have shown
that pharmacological inhibition of FABPs elevates brain
levels of AEA. Similarly, others have demonstrated
that mice lacking FABP5 likewise possess elevated
brain AEA levels [6, 13]. Pharmacological inhibition of
FABPs produces antinociceptive effects that are mediated by both CB1 and PPARα, suggesting the involvement of endocannabinoids and NAEs such as PEA [6,
14].
To date, it is not known whether mice deficient in
FABP5 and FABP7 exhibit alterations in NAE and endocannabinoid levels and/or show altered nociception.
Herein, we characterize the endocannabinoid system in
mice lacking both FABP5 and FABP7 and provide evidence that these FABPs regulate the endocannabinoid/
NAE tone in vivo. Furthermore, we examined nociception in these animals and demonstrate that the antinociceptive effects observed in these mice involve multiple
receptors.
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Results
Characterization of the endocannabinoid system
in FABP5/7 KO mice

Generation of the FABP5/7 KO mice has been previously described [15]. We examined the expression of all
ten FABP subtypes (FABP1-9 and FABP12) in the brains
of WT and FABP5/7 KO mice. As expected, FABP3,
FABP5, and FABP7 were expressed in WT brains and
FABP5 and FABP7 were selectively deleted in FABP5/7
KO mice (Fig. 1a, b). Compensatory upregulation of
other FABP subtypes was not observed in the brains of
FABP5/7 KO mice (Fig. 1a). Previous work has shown
that pharmacological FABP inhibition elevates brain
endocannabinoid levels [6]. We confirmed that levels
of the endocannabinoid AEA were likewise elevated
in the brains of FABP5/7 KO mice (Fig. 1c). Furthermore, levels of the NAEs PEA and OEA were likewise
elevated. 2-AG levels seemed slightly elevated but this
did not reach statistical significance (p = 0.06). To
confirm that the elevations in endocannabinoid/NAE
levels were not due to changes in FAAH activity, AEA

Fig. 1 Characterization of the brain endocannabinoid system in FABP5/7 KO mice. a RT-PCR analysis of FABP expression in brains of WT and
FABP5/7 KO mice. Note that of the ten FABP isoform profiled, selective deletion of FABP5 and FABP7 was observed in the brains of FABP5/7 KO
mice. b Western blot confirms the absence of FABP5 and FABP7 in the brains of FABP5/7 KO mice. c Brain PEA, OEA, AEA, and 2-AG levels in WT and
FABP5/7 KO mice. *p < 0.05; **p < 0.01; ***p < 0.001 (n = 6). d Hydrolysis of AEA in brain homogenates of WT and FABP5/7 KO mice. e Representative western blots of brain FAAH, MAGL, COX-2, NAPE-PLD, and CB1 expression in WT and FABP5/7 KO mice. f Quantification of western blots
expressed as a ratio of fold change between FABP5/7 KO and WT mice
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hydrolysis was examined in homogenates of brains
from WT and FABP5/7 KO mice and no differences
in AEA hydrolysis were observed between the genotypes (Fig. 1d). Lastly, we employed western blotting to
examine changes in expression of proteins associated
with the endocannabinoid system in FABP5/7 KO mice.
There were no changes in CB1 receptor levels or in the
expression of the endocannabinoid/NAE biosynthetic
enzyme N-acyl phosphatidylethanolamine phospholipase D (NAPE-PLD) or the endocannabinoid catabolic
enzymes FAAH, monoacylglycerol lipase (MAGL),
and cyclooxygenase-2 (COX-2) (Fig. 1e, f ). These data
indicate that FABP5/7 KO mice possess elevated endocannabinoid/NAE levels, consistent with their role of
gating the catabolism of endocannabinoids/NAEs by
their respective enzyme(s).
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Nociception in FABP5/7 KO mice

Baseline nociception was examined in WT and FABP5/7
KO mice. There were no differences in tail withdrawal
latencies between the genotypes in the tail immersion
test (Fig. 2a). Similarly, there were no differences in baseline thermal withdrawal latencies in the Hargreaves test
(Fig. 2b). However, clear differences emerged in mice
subjected to an inflammatory insult. In the carrageenan
model of peripheral inflammation, WT mice developed
thermal hyperalgesia and this was significantly attenuated
in FABP5/7 KO mice (Fig. 2b). Furthermore, FABP5/7
KO exhibited reduced paw edema following carrageenan
challenge (Fig. 2c).
We assessed FABP5/7 KO mice in two additional
pain models. In the formalin test, FABP5/7 KO mice
showed reduced nociception during the first phase of

Fig. 2 Nociception in FABP5/7 KO mice. a Tail withdrawal latencies of WT and FABP5/7 KO mice in the tail immersion test (n = 6). b Paw withdrawal
latencies in the hargreaves test in WT (white bars) and FABP5/7 KO (blue bars) mice before and 4 h after carrageenan injection. **p < 0.01 versus
carrageenan injected WT mice (n = 6). c Paw edema in WT and FABP5/7 KO mice after carrageenan injection (n = 6). d Nociception during the
first (left panel 0–5 min) and second (right panel 15–60 min) phases of the formalin test. *p < 0.05 (n = 9). e Acetic acid writhing in WT and FABP5/7
KO mice. The FABP5/7 KO mice received a subcutaneous injection of vehicle, 3 mg/kg rimonabant, or 4 mg/kg GW6471 45 min before acetic acid
injection. *p < 0.05 versus WT mice; #p < 0.05 versus vehicle-treated FABP5/7 KO mice (n = 9–12). f Carrageenan-induced thermal hyperalgesia in
WT and FABP5/7 KO mice treated with receptor antagonists. FABP5/7 KO mice were injected with vehicle, 3 mg/kg rimonabant, 3 mg/kg SR144528,
4 mg/kg GW6471, or 5 mg/kg capsazepine before carrageenan administration. *p < 0.05; **p < 0.01 versus carrageenan injected WT mice. #p < 0.05;
##
p < 0.01 versus carrageenan injected FABP5/7 KO mice (n = 9–12)
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the test (Fig. 2d). In the acetic acid test, FABP5/7 KO
mice showed an attenuated writhing response (Fig. 2e).
The receptor(s) mediating the antinociceptive effects
in FABP5/7 KO mice were subsequently examined.
We focused upon CB1 and PPARα receptors because
FABP5/7 KO mice possess elevated levels of NAEs that
serve as ligands for both of these receptors. In the acetic
acid writhing test, treatment of mice with the CB1 antagonist rimonabant or the PPARα antagonist GW6471
completely reversed the antinociceptive phenotype found
in FABP5/7 KO mice (Fig. 2e). The involvement of these
receptors was also examined in the carrageenan model.
Consistent with the acetic acid test, GW6471 reversed
the antinociceptive phenotype of FABP5/7 KO mice
(Fig. 2f ). Surprisingly, treatment of mice with rimonabant
or the CB2 antagonist SR144528 alone or in combination
did not block the analgesic effects observed in FABP5/7
KO mice.
Previous studies have demonstrated that activation of
transient receptor potential vanilloid 1 (TRPV1) within
the brain produces analgesia [16, 17]. Because AEA is a
TRPV1 agonist [18] and its levels are elevated in FABP5/7
KO mice, we examined whether these receptors may
likewise mediate the antinociceptive effects observed
in FABP5/7 KO mice. Indeed, the TRPV1 antagonist
capsazepine reduced thermal withdrawal latencies in
FABP5/7 KO mice (Fig. 2f ). These data indicate that
FABP inhibition results in the upregulation of endocannabinoids/NAEs that produce analgesia by engaging multiple receptor systems.
The pain models employed herein measure evoked
responses, effects that can be confounded by motor
impairment. Consequently, we examined whether
FABP5/7 KO mice exhibit motor deficits. In the open
field test and rotarod tests, there were no differences
between WT and FABP5/7 KO mice (Fig. 3a, b). We also
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profiled 24 h circadian home cage behavior and found no
differences in home cage activity between the genotypes
with the exception of enhanced locomotion in FABP5/7
KO mice at one time interval (Fig. 3c). These data indicate that FABP5/7 KO mice, similar to FABP inhibitor
treated mice [6], do not possess motor deficits.

Discussion
Endocannabinoids and NAEs reduce nociception
through engagement of central and peripheral CB1 and
PPARα receptors [11, 19]. Endocannabinoid inactivation
proceeds through cellular uptake followed by intracellular hydrolysis [20]. Cytoplasmic FABPs transport endocannabinoids/NAEs to their catabolic enzyme(s) and
are ideally situated to control endocannabinoid/NAE
metabolism [4]. Consequently, therapeutic targeting of
FABPs may serve as a novel strategy for the development
of analgesic and anti-inflammatory drugs [6, 14].
Previous work by us and others has demonstrated that
inhibition of FABPs reduces the cellular uptake of endocannabinoids [4, 21]. Consequently, pharmacological
FABP inhibition and genetic FABP5 ablation results in
elevated AEA levels [6, 13]. Herein we confirm that mice
lacking FABP5 and FABP7, the brain-expressed FABPs
with highest affinities for endocannabinoids/NAEs show
markedly elevated AEA levels. The relatively similar elevations in AEA levels between FABP5/7 KO mice and
FABP5 KO mice [13] suggests that the contribution of
FABP7 towards regulating the AEA tone may be minimal. This is consistent with the low expression level of
FABP7 in the adult mouse brain [22]. In addition to AEA,
we demonstrate for the first time that ablation of FABPs
results in elevated PEA and OEA levels, indicating that
FABPs are important regulators of the NAE tone in vivo.
We have recently reported that mice treated
with FABP5 and FABP7 selective inhibitors display

Fig. 3 Motor activity in WT and FABP5/7 KO mice. a Locomotion in the open field test in WT and FABP5/7 KO mice (n = 6). b Latency to fall in the
rotarod test for WT and FABP5/7 KO mice (n = 8–16). c Home cage activity over a 24-h period in WT and FABP5/7 KO mice. *p < 0.05 versus WT mice
(n = 14)
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antinociceptive effects when subjected to diverse
pain models [6, 14]. In support of this, we demonstrate here that mice lacking FABP5 and FABP7 possess a similar antinociceptive phenotype. Similar to
acute pharmacological FABP inhibition, the antinociceptive effects in FABP5/7 KO mice are mediated by
CB1 and PPARα receptors. Unexpectedly, blockade
of CB1 receptors with rimonabant failed to reverse
the analgesic effects in the carrageenan model, which
contrasts to our previous results following acute pharmacological FABP inhibition [14]. This may reflect
possible adaptive changes in response to chronic
endocannabinoid elevation, although the exact mechanism responsible for this discrepancy requires further elucidation. Although rimonabant also engages
TRPV1 [23], the use of identical rimonabant doses
in our prior and current study suggest that its lack
of efficacy is unlikely to stem from off-target effects
at TRPV1. Furthermore, using a TRPV1 antagonist,
we provide evidence that TRPV1 receptors likewise
mediate the analgesic effects observed in FABP5/7 KO
mice, consistent with an established role of supraspinal TRPV1 in pain modulation [16, 17]. Although we
hypothesize that this effect may be mediated by elevated levels of the TRPV1 agonist AEA, it is likewise
possible that other FABP-regulated TRPV1 ligands
may mediate this effect.

Conclusions
In summary, this study provides evidence that FABP5
and FABP7 contribute to endocannabinoid/NAE metabolism in vivo and establishes these proteins as important
regulators of the NAE and endocannabinoid tone. The
observation that FABP5/7 KO mice display inflammation-associated analgesia but unchanged baseline thermal withdrawal latencies suggests that inflammation
unmasks a role for FABP-regulated ligands in pain modulation. Therefore, pharmacological agents that selectively
disrupt FABP function may serve as novel analgesics.
Future studies aimed at characterizing the contribution
of peripherally and centrally expressed FABPs toward
nociception are required to conclusively delineate the
anatomical site(s) of FABP-mediated analgesia.
Methods
Chemicals and drugs

PEA, d4-PEA, OEA, d2-OEA, 2-AG and d5-2-AG
were from Cayman Chemical while AEA and d4-AEA
were from R&D systems. [14C]AEA, rimonabant and
SR144528 were obtained from the Drug Supply Program
at the National Institute on Drug Abuse. GW6471 was
purchased from Sigma while capsazepine was purchased
from Cayman Chemical.
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Animals

Male C57Bl/6 mice (2–3 months old) were purchased
from Jackson Laboratories. FABP5/7 KO mice were previously described [15]. The animals were group housed
and had ad libitum access to food and water. The animals
were habituated to handling in the experimental room
for at least 1 day before each experimental session. The
experiments were approved by the Stony Brook University Institutional Animal Care and Use Committee
(#277150).
Drug administration

Receptor antagonists were injected 30 min before behavioral measurements and were administered in a volume of 10 µl/g body weight. Rimonabant and SR144528
(3 mg/kg) were dissolved in saline containing 5 % ethanol and 5 % cremophor-EL. GW6471 (4 mg/kg) was
dissolved in saline containing 2 % DMSO and 5 % cremophor-EL. Capsazepine (5 mg/kg) was dissolved in saline
containing 2 % DMSO and 10 % Tween 80. The antagonists were administered via the intraperitoneal route with
the exception of the acetic acid test where the drugs were
injected subcutaneously.
Nociceptive tests

The formalin, acetic acid writhing, and carrageenaninduced inflammatory pain models were performed
exactly as described [6]. For the tail immersion test, mice
were gently restrained and one cm of the tail was submerged in a water bath set at 56 °C. The latency to withdraw the tail from the water bath was measured using a
stopwatch.
Motor tests

In the open field test, mice were placed in the open
field chamber containing a laser beam grid (San Diego
Instruments) and beam breaks indicative of locomotion
were scored over a 5 min period. The rotarod test using
a rotarod apparatus (Rotamex 0192-100 M, Columbus
Instruments) was used to examine motor coordination by
measuring the ability of mice to remain on a rotating rod.
During each trial, the rotating rod accelerated a linear
rate from a set starting rate of 4 RPM to a set ending rate
of 40 RPM, all within a 5 min time frame. Subjects were
observed throughout the test, and falls from the axle,
including time and fall speed, are automatically recorded
by the apparatus. Subjects that cling to the axle—remaining stationary as they rotate with the axle—are recorded
as a “passive rotation”. Latency to fall or commit a passive
rotation is measured by the apparatus. Subjects whose
latency to fall or commit a passive rotation exceeds the
designated 5 min “passes” the given trial. Subjects who
fail to do so “fail” the trial. Home cage circadian activity
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was measured for each mouse for a period of 72 h. The
first 24 h acted as a habituation period and no measurements were taken. Each half-hour time point from
the two recorded days was averaged together for each
subject.
Lipid quantification

Endocannabinoid/NAE quantification was performed
exactly as described [6].
Enzyme assays

AEA and 2-OG hydrolysis was performed exactly as
described [6].
RT‑PCR

Mouse brains were homogenized and cDNA synthesis commenced as previously described [5]. The
cDNA was amplified using LongAmp Taq DNA polymerase (New England Biolabs) using gene specific
primers. The following primers were used: FABP1:
5′-TCATGAAGGCAATAGGTCTG-3′
and
5′-G
TTCAGTCACGGACTTTATGC -3′; FABP2: 5′-GAA
AATGGGCATTAATGTGATGA-3′ and 5′-AGAAAC
CTCTCGGACAGCAA-3′; FABP3: 5′-CATCGAGAAGA
ACGGGGATA-3′ and 5′-TGCCATGAGTGAGAGTC
AGG-3′; FABP4: 5′-AGTGGCAGGCATGGCCAAG
C-3′ and 5′-GTCACCATCTCGTTTTCTC-3′; FAB
P5: 5′-AGGAAGATGGCTGCCATGG-3′ and 5′-TGTT
CATGACACACTCCAC-3′; FABP6: 5′-CATGAAGCGC
CTGGGTCT-3′ and 5′-AACTTGTCACCCACGACC
TC-3′; FABP7: 5′-AGTGGGAAACGTGACCAAAC-3′
and 5′-TTTCTTTGCCATCCCACTTC-3′; FABP8: 5′-CT
ACATGAAAGCTCTAGGTGTGG-3′ and 5′-TCTC
CAGTGTCACGATGCTC-3′; FABP9: 5′-GTGAGAGAA
CTGGGAGTGGAAT-3′
and
5′-AGCCATTTTT
GGACCTGGAT-3′;
FABP12:
5′-ATGAAGGAATT
GGGAGTAGGAAG-3′ and 5′-CCTGGACTTGAACC
AAGGAG-3′; GAPDH: 5′-CGAGACCCCACTAACATC
AAA-3′ and 5′-CTTCCACAATGCCAAAGTTGT-3′.

Page 6 of 7

quantify changes in protein expression between WT and
FABP5/7 KO mice, ratios of normalized protein intensities were compared between the genotypes.
Statistical analysis

Behavioral data are presented as mean ± SEM of at
least six animals per group. Biochemical data are presented as mean ± SEM of at least three independent
experiments performed in triplicate. Statistical significance was determined using unpaired t-tests or oneway ANOVA followed by Dunnett or Tukey post hoc
analyses as appropriate. Home cage activity was analyzed by two-way ANOVA followed by Bonferroni post
hoc test. In all cases, differences of p < 0.05 were considered significant.
Abbreviations
FABP: fatty acid binding protein; FAAH: fatty acid amide hydrolase; CB1:
cannabinoid receptor 1; CB2: cannabinoid receptor 2; PPARα: peroxisome
proliferator-activated receptor alpha; MAGL: monoacylglycerol lipase; NAPEPLD: N-acyl phosphatidylethanolamine phospholipase D; COX2: cyclooxygenase-2; RT-PCR: reverse transcription polymerase chain reaction.
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Western blotting

Western blot experiments were performed as described
[5]. Blots were probed with the following antibodies: COX2 (1:1000, Abcam #Ab15191), FAAH (1:1000,
Abcam #Ab54615), MAGL (1:400, Cayman Chemical #10212), GAPDH (1:5000, Abcam #Ab8245), CB1
(1:1000, Abcam #Ab172970), NAPE-PLD (1:400,
Abcam #Ab95397), FABP5 (1:1000, BioVendor R&D
#RD181060100), or FABP7 (1:200, Abcam #Ab32423).
The blots were developed using the Immun-star HRP
substrate (Bio-Rad) and scanned using a C-DiGiT scanner (Li-COR). Protein band intensities were quantified
and normalized to the respective GAPDH intensities. To
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